piperacillin + tazobactam + amoxicillin + clavulanate

This is a combination of two beta-lactam/beta-lactamase inhibitor pairs—piperacillin with tazobactam and amoxicillin with clavulanate. Both combinations are used to treat a wide range of bacterial infections, including those caused by beta-lactamase-producing organisms. Piperacillin and amoxicillin are penicillin-class antibiotics that inhibit bacterial cell wall synthesis, leading to cell death. Tazobactam and clavulanate are beta-lactamase inhibitors that protect the antibiotics from enzymatic degradation by resistant bacteria, thereby extending their spectrum of activity[2][5][9][10]. This quadruple combination would theoretically provide very broad antibacterial coverage against Gram-positive, Gram-negative (including Pseudomonas aeruginosa), and anaerobic pathogens. However, there is no evidence this four-drug combination is available as a single marketed product or routinely used in clinical practice; instead, piperacillin/tazobactam and amoxicillin/clavulanate are typically administered separately for specific indications[1][3][4].